ライフサイエンスコーパス: TDF

1 TDF administered to wild-type (wt) and GFAP-gp120 transg

2 TDF also increased expression of GFAP and decreased expr

3 TDF also reduced IL-1beta-mediated increases in IL-1beta

4 TDF completely suppressed HBV DNA in 131 patients (92 %)

5 TDF increased tumor necrosis factor (TNF) alpha in wt mi

6 TDF intake was associated with a decreased risk of breas

7 TDF PrEP prevented vaginal HIV acquisition in a dose-dep

8 measured the DNA methylation profiles of 10 TDFs from OAC with 12 NDF from normal oesophageal mucosa

9 760 [41.7%]; ARR, 1.15; 95% CI, 1.04-1.27); TDF-FTC and lopinavir-ritonavir (TDF-FTC-LPV-R) (112 of

10 hat period, the average total payment for 30 TDF-FTC tablets increased from $1350 to $1638 (5.0% comp

11 Of the $1638 in total payments per 30 TDF-FTC tablets in 2018, OOP payments accounted for $94

12 Third-party and OOP payments per 30 TDF-FTC tablets increased annually.

13 BC/3TC) or FTC/TDF in DRIVE-FORWARD; and 3TC/TDF for DOR and FTC/TDF for EFV in DRIVE-AHEAD.

14 were significantly different between DOR/3TC/TDF and EFV/FTC/TDF (-1.6 vs +8.7 mg/dL and -3.8 vs +13.

15 In HIV-1 treatment-naive adults, DOR/3TC/TDF demonstrated non-inferior efficacy to EFV/FTC/TDF at

16 At week 48, 84.3% (307/364) of DOR/3TC/TDF recipients and 80.8% (294/364) of EFV/FTC/TDF recipi

17 DOR/3TC/TDF recipients had significantly lower rates of dizzines

18 disoproxil fumarate (TDF) at 300 mg (DOR/3TC/TDF) or to efavirenz at 600 mg, emtricitabine at 200 mg,

19 ts) and as a fixed-dose combination (DOR/3TC/TDF), demonstrated noninferior efficacy to DRV+r and EFV

20 n 5 (MVC), 13 (MVC-FTC), 9 (MVC-TDF), and 8 (TDF-FTC) participants; rates did not differ among regime

21 s load (VL) in patients failing therapy on a TDF/XTC plus nonnucleoside reverse-transcriptase inhibit

22 s load (VL) in patients failing therapy on a TDF/XTC plus nonnucleoside RT inhibitor (NNRTI)-containi

23 sons with and without M184V/I during VF on a TDF/XTC/NNRTI-containing regimen.

24 ency virus RNA suppression while receiving a TDF- or tenofovir alafenamide-containing regimen.

25 the performance of models formulated with a TDF(CAM) against other relevant TDFs and assessed model

26 n stable isotope mixing models fitted with a TDF(CAM) and uninformative prior had the best agreement

27 BSIMMs produced with a TDF(CAM) produced reliable diet estimates at the nest le

28 pate in a behavioral intervention and accept TDF/FTC as PrEP.

29 s and TDF did not result in major additional TDF-related renal toxicity in HIV-infected patients.

30 ar mass black holes, which suggests that all TDFs could be accompanied by a jet.

31 (r(2) = 0.98) is observed between the AX and TDF contents indicating that AX can be used to estimate

32 ng stavudine (d4T), azidothymidine (AZT) and TDF on death and attrition among HIV patients with HBV c

33 ell-based assay, TAF was 35- and 24-fold and TDF was 10- and 7-fold more potent than acyclovir and pe

34 nt incidental exposure to MRP inhibitors and TDF did not result in major additional TDF-related renal

35 renz at 600 mg, emtricitabine at 200 mg, and TDF at 300 mg (EFV/FTC/TDF) for 96 weeks.

36 nge {IQR}, 0.08-0.30]; n = 372), LDV/SOF and TDF/PI (0.17 [IQR, 0.04-0.30]; n = 100), and LDV/SOF wit

37 th either of two tenofovir prodrugs (TAF and TDF) showed noninferior efficacy to treatment with the s

38 nal TFV distribution differs between TAF and TDF.

39 re observed in semen quality between TAF and TDF.

40 FV-dp C24 in SMC was comparable with TAF and TDF.

41 lus tenofovir disoproxil fumarate (TDF), and TDF plus FTC.

42 MVC-tenofovir disoproxil fumarate (TDF), and TDF-FTC (control).

43 it is challenging to select the appropriate TDF for diet estimation in wild populations.

44 patitis B, TAF appears to be as effective as TDF, with lower bone and renal toxicity.

45 In astroglia, TDF caused a dose-dependent increase in oxygen consumpti

46 , and hepatitis B virus DNA were obtained at TDF initiation and every 6-12 months.

47 lts of participants enrolled in the Botswana TDF/FTC Oral HIV Prophylaxis Trial, the Bangkok Tenofovi

48 contrast, total dietary fibre concentration (TDF) was higher in DFC-BE (81.82 g/100 g DW) in comparis

49 mong infants exposed to ART from conception, TDF-FTC-EFV was associated with a lower risk for adverse

50 The ART containing TDF had a significantly lower risk of death [adjusted ha

51 The ART containing TDF had significant effects on both of death and attriti

52 HBV coinfection receiving the ART containing TDF had significantly lower risk rates of attrition comp

53 ither for their total dietary fibre content (TDF) and their arabinoxylan (AX) content.

54 ntaining antiretroviral regimen or continued TDF, we estimated changes in eGFR and urine protein-to-c

55 ths in patients with >/=1 year of continuous TDF exposure.

56 ipants were randomized to receive controlled TDF/FTC dosing as (1) "perfect" adherence (daily); (2) "

57 Conversely TDF protected gp120-tg mice from cognitive dysfunction.

58 In a study of daily TDF/emtricitabine (FTC) preexposure prophylaxis (PrEP) i

59 al intervention and were provided with daily TDF/FTC as PrEP for 48 weeks.

60 ase of the ANRS IPERGAY trial with on demand TDF/FTC for HIV prevention and the impact of doxycycline

61 IV-infected, HSV-2-uninfected persons during TDF-containing ART.

62 oxil fumarate, emtricitabine, and efavirenz (TDF-FTC-EFV) (901 of 2472 [36.4%]) compared with TDF-FTC

63 PI or NNRTI and a backbone containing either TDF/FTC or ABC/3TC.

64 of peginterferon alfa-2a weekly plus either TDF (300 mg once daily) or placebo for 96 weeks.

65 fovir disoproxil fumarate and emtricitabine (TDF-FTC) for preexposure prophylaxis (PrEP) is an effect

66 fovir disoproxil fumarate and emtricitabine (TDF/FTC) co-formulate for use in pre-exposure prophylaxi

67 tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for PrEP is only licensed for adults.

68 were randomized to tenofovir-emtricitabine (TDF/FTC) plus atazanavir-ritonavir (ATV/r), darunavir-ri

69 with a backbone of tenofovir/emtricitabine (TDF/FTC) or abacavir/lamivudine (ABC/3TC).

70 umarate (TDF) and dolutegravir/emtricitabine/TDF arms.

71 s indicating that AX can be used to estimate TDF content in wheat products.

72 We introduce a novel method for estimating TDFs in a wild population-a proportionally balanced equa

73 loped in patients older than 50 years at ETV/TDF onset.

74 The HCC risk decreases beyond year 5 of ETV/TDF therapy in Caucasian chronic hepatitis B patients, p

75 nts without HCC at baseline who received ETV/TDF for >/=1 year.

76 ce beyond year 5 of entecavir/tenofovir (ETV/TDF) therapy and tried to determine possible factors ass

77 Here, we evaluate TDF and FTC in combination with the broadly neutralizing

78 CSF and total plasma concentrations of EVG, TDF, TAF, tenofovir (TFV), and HIV RNA levels were measu

79 Nine participants switched from E/C/F/TDF (150/150/200/300 mg once daily) to E/C/F/TAF (150/15

80 m E/C/F/tenofovir disoproxil fumarate (E/C/F/TDF 150/150/200/300 mg once daily) to E/C/F/TAF (150/150

81 change in participants switching from E/C/F/TDF to E/C/F/TAF.

82 nofovir disoproxil fumarate-emtricitabine (F/TDF) for HIV preexposure prophylaxis (PrEP) in the Unite

83 At a 50% discount for generic F/TDF ($8300 per year) and a societal willingness to pay u

84 In the presence of a generic F/TDF alternative, the improved safety of F/TAF is worth n

85 Preexposure prophylaxis with F/TAF versus F/TDF.

86 Over a 5-year horizon, compared with F/TDF, F/TAF averted 2101 fractures and 25 cases of ESRD f

87 ats exhibit a trophic discrimination factor (TDF) similar to other terrestrial organisms and that del

88 Tumour derived fibroblasts (TDFs) differ functionally from normal fibroblasts (NDFs)

89 own thermal stellar tidal disruption flares (TDFs) have not yet produced a conclusive detection.

90 analyses found efficacy estimates of 67% for TDF and 75% for TDF/FTC.

91 fficacy estimates of 67% for TDF and 75% for TDF/FTC.

92 the Swiss HIV Cohort Study who switched from TDF to TAF-containing antiretroviral regimen or continue

93 Switching from TDF to TAF improves eGFR and proteinuria in patients wit

94 he frequency of tubulopathy was 1.7% for FTC-TDF versus 1.3% for placebo (odds ratio, 1.30; 95% confi

95 Daily oral FTC-TDF PrEP was not significantly associated with tubulopat

96 Of 1549 persons studied (776 receiving FTC-TDF, 773 receiving placebo), 64% were male, and the medi

97 n DRIVE-FORWARD; and 3TC/TDF for DOR and FTC/TDF for EFV in DRIVE-AHEAD.

98 mone concentrations were not affected by FTC/TDF PrEP use.

99 EVG/c/FTC/TDF led to greater decreases in sCD14, hsCRP, and Lp-PLA

100 after 4 weeks of directly observed daily FTC/TDF PrEP use.

101 ly different between DOR/3TC/TDF and EFV/FTC/TDF (-1.6 vs +8.7 mg/dL and -3.8 vs +13.3 mg/dL, respect

102 with FTC/TDF or ABC/3TC (n = 383) or EFV/FTC/TDF (600/200/300 mg daily; n = 364).

103 emonstrated non-inferior efficacy to EFV/FTC/TDF at week 48 and was well tolerated, with significantl

104 DF recipients and 80.8% (294/364) of EFV/FTC/TDF recipients achieved <50 HIV-1 RNA copies/mL (differe

105 ltered sensorium (4.4% vs 8.2%) than EFV/FTC/TDF recipients.

106 tabine at 200 mg, and TDF at 300 mg (EFV/FTC/TDF) for 96 weeks.

107 in LDL-C and non-HDL-C compared with EFV/FTC/TDF.

108 3 for DRV+r, and 188.4 cells/mm3 for EFV/FTC/TDF.

109 P, and Lp-PLA2 levels, compared with EFV/FTC/TDF.

110 icitabine/tenofovir disoproxil fumarate (FTC/TDF) in P007; abacavir/lamivudine (ABC/3TC) or FTC/TDF i

111 l emtricitabine/TFV disoproxil fumarate (FTC/TDF).

112 abine and tenofovir disoproxil fumarate (FTC/TDF).

113 We report the effect of FTC/TDF on BMD in HIV-seronegative men who have sex with men

114 n P007; abacavir/lamivudine (ABC/3TC) or FTC/TDF in DRIVE-FORWARD; and 3TC/TDF for DOR and FTC/TDF fo

115 r up to 16 weeks and received placebo or FTC/TDF pericoitally.

116 Oral FTC/TDF maintains efficacy in a macaque model of sexually tr

117 for the intermittent gel and daily oral FTC/TDF regimens, but lower for the daily gel regimen.

118 y in the event of no RAI), or daily oral FTC/TDF.

119 In HIV-uninfected persons, FTC/TDF PrEP was associated with small but statistically sig

120 y gel use for HIV protection compared to FTC/TDF (OR, 0.38; P < .001).

121 RAI gel (IRR, 0.90; P = .51) compared to FTC/TDF.

122 pared with DRV+r (800/100 mg daily) with FTC/TDF or ABC/3TC (n = 383) or EFV/FTC/TDF (600/200/300 mg

123 DOR [100 mg daily] with emtricitabine [FTC]/TDF or abacavir [ABC]/3TC [n = 747]) compared with DRV+r

124 had ever used tenofovir disoproxil fumarate (TDF) (1.40; 1.15-1.70) or who were currently on TDF (1.2

125 sed group) or tenofovir disoproxil fumarate (TDF) (TDF-based group) - against the local standard-of-c

126 etic study of tenofovir disoproxil fumarate (TDF) 300 mg/emtricitabine (FTC) 200 mg among adults livi

127 emtricitabine/tenofovir disoproxil fumarate (TDF) and dolutegravir/emtricitabine/TDF arms.

128 Oral tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) are effective in HIV-1 pre-

129 ombination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) or placebo before and after

130 combined with tenofovir disoproxil fumarate (TDF) and pegylated interferon alfa-2a (pegIFN) in patien

131 marketed, and tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) have also proved ef

132 we show that tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF), drugs with excelle

133 some form of tenofovir disoproxil fumarate (TDF) as part of their HIV treatment regimen.

134 t 300 mg, and tenofovir disoproxil fumarate (TDF) at 300 mg (DOR/3TC/TDF) or to efavirenz at 600 mg,

135 spread use of tenofovir disoproxil fumarate (TDF) in pregnant and breastfeeding women, few data exist

136 Tenofovir disoproxil fumarate (TDF) is associated with proximal tubular dysfunction (tu

137 Tenofovir disoproxil fumarate (TDF) is commonly used in antiretroviral treatment (ART)

138 Tenofovir disoproxil fumarate (TDF) is one of the nucleotide analogs capable of inhibit

139 Exposure to tenofovir disoproxil fumarate (TDF) may cause renal toxicity.

140 s of systemic tenofovir disoproxil fumarate (TDF) PrEP revealed reduced efficacy in women compared to

141 and increased tenofovir disoproxil fumarate (TDF) susceptibility.

142 ng from E/C/F/tenofovir disoproxil fumarate (TDF) to E/C/F/TAF.

143 w response to tenofovir disoproxil fumarate (TDF) treatment, have been examined to identify structura

144 lled trial of tenofovir disoproxil fumarate (TDF) use from 28 weeks gestational age to 2 months postp

145 e (E/C/F) and tenofovir disoproxil fumarate (TDF) who switched to E/C/F and TAF.

146 Replacing tenofovir disoproxil fumarate (TDF) with tenofovir alafenamide (TAF) improves renal tub

147 g LDV/SOF and tenofovir disoproxil fumarate (TDF) without a protease inhibitor (PI) (0.18 [interquart

148 therapy with tenofovir disoproxil fumarate (TDF) would increase hepatitis D virus (HDV) RNA suppress

149 TC), MVC plus tenofovir disoproxil fumarate (TDF), and TDF plus FTC.

150 ne (FTC), MVC-tenofovir disoproxil fumarate (TDF), and TDF-FTC (control).

151 e high use of tenofovir disoproxil fumarate (TDF), emtricitabine, and lamivudine and potential transm

152 successor of tenofovir disoproxil fumarate (TDF), has been approved in the United States and Europe

153 who were receiving TFV disoproxil fumarate (TDF)-based therapy.

154 roc (MVC)- to tenofovir disoproxil fumarate (TDF)-containing ART.

155 ne changes in tenofovir disoproxil fumarate (TDF)-related bone toxicity.

156 (PLWH) taking tenofovir disoproxil fumarate (TDF).

157 formulation, tenofovir disoproxil fumarate (TDF).

158 itabine (FTC)/tenofovir disoproxil fumarate (TDF).

159 of the NRTIs tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC), tenofovir alafenamide (TAF)/FT

160 LWH receiving tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)/EFV 600 mg with a viral load (V

161 Tenofovir disoproxyl fumarate (TDF) disoproxyl fumarate (TDF) has in vitro activity aga

162 soproxyl fumarate (TDF) disoproxyl fumarate (TDF) has in vitro activity against herpes simplex virus

163 Tenofovir disproxil fumarate (TDF) has been shown to affect neurogenesis in brains of

164 ivudine [3TC]/tenofovir disoproxil fumarate [TDF] or DOR [100 mg daily] with emtricitabine [FTC]/TDF

165 y merit a downward adjustment, using generic TDF-based costs as the benchmark.

166 However, TDF reduced interleukin (IL) 1beta and TNFalpha mRNA in

167 to determine bone mineral density changes in TDF-exposed patients.

168 f which 3,243 (66.8%) were hypomethylated in TDFs compared to NDFs.

169 When administered at 50 mg/kg, TDF achieved plasma TFV concentrations (370 ng/ml) that

170 intervention in conjunction with open-label TDF/FTC.

171 tions (ng/mL) for perfect, moderate, and low TDF adherence were 41 (26-52), 16 (14-19), and 4 (3-5) i

172 Maternal TDF use did not adversely affect perinatal outcomes.

173 there was no significant effect of maternal TDF use on maternal or infant bone mineral density 1 yea

174 In the brains of wt and gp120-tg mice, TDF decreased expression of mitochondrial transcription

175 acquired HIV infection (4 MVC alone, 1 MVC + TDF; overall annualized incidence, 1.4% [95% confidence

176 ts occurred in 5 (MVC), 13 (MVC-FTC), 9 (MVC-TDF), and 8 (TDF-FTC) participants; rates did not differ

177 One death (by suicide) occurred in the MVC-TDF group but was judged not to be related to study drug

178 Neither TDF nor TFV gel decreased overall shedding or lesion rat

179 In patients without viral suppression, no TDF-related resistance mutations were found.

180 e safety, tolerability, and acceptability of TDF/FTC and patterns of use, rates of adherence, and pat

181 Addition of TDF resulted in no significant improvement in HDV RNA re

182 tures indicates no difference in affinity of TDF binding by RT encoded by intra-host HBV variants tha

183 00 over the average wholesale price (AWP) of TDF.

184 A backbone of TDF/FTC was received by 67% of PI users and 69% of NNRTI

185 stroglia were exposed to increasing doses of TDF for 24 hours and then analyzed for mitochondrial alt

186 The median duration of TDF exposure was 54 months, and the total cumulative exp

187 This finding suggests that effectiveness of TDF recognition and binding does not contribute signific

188 increased in astroglia in the hippocampi of TDF-treated wt and gp120-tg mice.

189 Inhibitors of TDF's apical multidrug-resistance-associated protein eff

190 4; 95% CI, 1.19 to 3.85) since initiation of TDF therapy.

191 Our method of TDF estimation produced more accurate estimates of TDFs

192 at rapidly decline or persist in presence of TDF.

193 gainst the local standard-of-care regimen of TDF-FTC-efavirenz (standard-care group).

194 dings support the short-term renal safety of TDF/FTC PrEP in HIV-seronegative young men and suggest t

195 >=90 mL/min, eGFR decreased with the use of TDF and TAF (-1.7 mL/min).

196 /min (95% CI, 2.3-9.3) with continued use of TDF in individuals with baseline eGFR <60 mL/min.

197 reassuring and support the continued use of TDF in pregnancy.

198 During the first 24 weeks of TDF and pegIFN administration, significantly higher prop

199 with 10-24 weeks, and 188 with <10 weeks of TDF exposure.

200 timation produced more accurate estimates of TDFs in a wild population than traditional approaches, c

201 ) (1.40; 1.15-1.70) or who were currently on TDF (1.25; 1.05-1.49) had higher incidence of fractures.

202 n duration of HBV persistence in patients on TDF therapy suggests the existence of genetic mechanisms

203 ith hepatic decompensation and was placed on TDF therapy.

204 DP in DBS predicts future viremia in PLWH on TDF, even in those who are virologically suppressed.

205 ciated with virologic suppression in PLWH on TDF-based therapy and is associated with certain partici

206 (up to 3 visits within 48 weeks) in PLWH on TDF.

207 ith few specific mutations in RT, the HBV on-TDF persistence is defined by genetic variations across

208 led (i.e. a trophic discrimination factor or TDF).

209 ized, placebo-controlled trial of daily oral TDF, alone or with emtricitabine (FTC), in HIV-uninfecte

210 reement with nest camera data, outperforming TDFs derived from captive feeding studies.

211 iety ought to be willing to pay for TAF over TDF, in exchange for its improved toxicity profile.

212 tients to receive peginterferon alfa-2a plus TDF and 61 to receive peginterferon alfa-2a plus placebo

213 groups (23 in the peginterferon alfa-2a plus TDF group and 25 in the peginterferon alfa-2a plus place

214 vents (459 in the peginterferon alfa-2a plus TDF group and 485 in the peginterferon alfa-2a plus plac

215 9 patients in the peginterferon alfa-2a plus TDF group and in 20 (33%) of 61 patients in the peginter

216 ween adverse perinatal outcomes and prenatal TDF use.

217 C/NVP (34%); 49% of pregnancies had prenatal TDF exposure and 6% used a protease inhibitor.

218 sed to determine the association of prenatal TDF and perinatal outcomes.

219 rend in the proportion of persons prescribed TDF-FTC for PrEP during the study period, with 417 users

220 persons aged >/=16 years who were prescribed TDF-FTC for PrEP each year.

221 om participants randomly assigned to receive TDF, TDF-FTC, and TFV gel, respectively.

222 ersons, 68 acquired HSV-2, with 24 receiving TDF-containing ART and 44 receiving ART without TDF (HSV

223 No patient receiving TDF/FTC was admitted to the ICU or died.

224 HIV-positive patients receiving TDF/FTC have a lower risk for COVID-19 and related hospi

225 >/=25 weeks were older than those receiving TDF for 10-24 or <10 weeks (median age, 31 vs 28 and 28

226 10.5 (CI, 5.6 to 17.9) among those receiving TDF/FTC, 23.4 (CI, 17.2 to 31.1) among those receiving A

227 d a suppressed viral load and were receiving TDF as a part of combination antiretroviral therapy.

228 Women receiving TDF for >/=25 weeks were older than those receiving TDF

229 care urine-based TFV assays to assess recent TDF adherence.

230 echanisms of on-drug persistence that reduce TDF efficacy for some HBV strains without affording actu

231 (1) provide additional safety data regarding TDF/FTC use among young MSM who had negative test result

232 lated with a TDF(CAM) against other relevant TDFs and assessed model sensitivity to an informative pr

233 UPCR decreased after replacing TDF by TAF, independent of baseline eGFR.

234 1.04-1.27); TDF-FTC and lopinavir-ritonavir (TDF-FTC-LPV-R) (112 of 231 [48.5%]; ARR, 1.31; 95% CI, 1

235 nests in lieu of a controlled feeding study (TDF(CAM) ).

236 odel to perform a PK-PD analysis of systemic TDF PrEP for vaginal HIV acquisition.

237 oup) or tenofovir disoproxil fumarate (TDF) (TDF-based group) - against the local standard-of-care re

238 rticipants randomly assigned to receive TDF, TDF-FTC, and TFV gel, respectively.

239 core antibody (qAnti-HBc) during tenofovir (TDF) treatment and assess their ability to predict hepat

240 e (FTC) resistance, and increased tenofovir (TDF) susceptibility.

241 and the nucleotide RTI inhibitor tenofovir (TDF), show efficacy in blocking K103 RT.

242 retroviral therapy (ART) based-on tenofovir (TDF) and/or lamivudine (3TC) in a real-world setting.

243 ug regimens (zidovudine [ZDV]- or tenofovir [TDF]-based regimens), and 10 studies (1755 initiations)

244 bolite to target cells more efficiently than TDF at lower doses, thereby reducing systemic exposure t

245 These data demonstrate that TDF causes peripheral neuropathy in mice and alterations

246 In this study, we hypothesized that TDF contributes to neurotoxicity by modulating mitochond

247 r metabolite (TFV diphosphate) revealed that TDF PrEP efficacy was best described by plasma TFV level

248 The TDF analogue tenofovir alafenamide (TAF) has demonstrate

249 At the time patients completed the TDF + pegIFN + NAP regimen, HBsAg levels were 0.05 IU/mL

250 6.4 kg in the TAF-based group, 3.2 kg in the TDF-based group, and 1.7 kg in the standard-care group).

251 r was 84% in the TAF-based group, 85% in the TDF-based group, and 79% in the standard-care group, fin

252 In the TDF-FTC group, as compared with the placebo group, there

253 ion may contribute to the maintenance of the TDF phenotype.

254 In the rest frame of the TDF, our radio observations are an order of magnitude mo

255 Vaginal administration of the TDF-FTC-VRC01-N combination holds significant promise fo

256 Multivariate analysis revealed that the TDF group had lower risk (odds ratio = 0.10, P = 0.0434)

257 REP 2165-Mg) or 24 weeks of control therapy (TDF + pegIFN) followed by 48 weeks of experimental thera

258 t received 48 weeks of experimental therapy (TDF + pegIFN + REP 2139-Mg or REP 2165-Mg) or 24 weeks o

259 on of variable radio emission from a thermal TDF, which we interpret as originating from a newly laun

260 (RR, N = 5) and slow response (SR, N = 5) to TDF.

261 shown that TAF may be a good alternative to TDF for treating chronic hepatitis B.

262 ences in patterns of genetic associations to TDF response between HBV genotypes B and C and lack of a

263 tion (PTH-FGF23) is a primary contributor to TDF-associated BMD decline in this age group.

264 less frequently among pregnancies exposed to TDF (aPRR, 0.34, P = .02).

265 o association between cumulative exposure to TDF and fractures (1.08/5 y exposure; 0.94-1.25).

266 een pregnancies with and without exposure to TDF in the frequency of pregnancy loss (adjusted prevale

267 Exposure to TDF, but not other ARVs, was an independent risk factor

268 zed trial, we found that addition of NAPs to TDF + pegIFN did not alter tolerability and significantl

269 There is no known HBV resistance to TDF.

270 d in patients with slow or rapid response to TDF treatment.

271 ons/T215rev, showed no impact on response to TDF- or tenofovir alafenamide-containing regimens.

272 ssociated with the differential responses to TDF treatment.

273 tions among intra-host variants sensitive to TDF indicate a complex genetic encoding of the trait.

274 a viral load (VL) <50 copies/mL switched to TDF/FTC/EFV400.

275 the intake of DFs of different types [total (TDF), soluble (SF), insoluble (IF)] and from different s

276 In coinfected patients undergoing TDF, qHBcrAg/qAnti-HBc could be of use in monitoring HBe

277 ssociations between the duration of in utero TDF exposure and change in FLZ and HLZ.

278 no association between duration of in utero TDF exposure per 1-week increment and change in FLZ (ss

279 The duration of in utero TDF exposure was calculated in weeks.

280 ist on fetal bone development after in utero TDF exposure.

281 Following 24 weeks TDF therapy, 40 patients were randomly assigned to group

282 The most frequent ART regimens were TDF/3TC/EFV (39%) and AZT/3TC/NVP (34%); 49% of pregnanc

283 Whether TDF-containing antiretroviral therapy (ART) reduces HSV-

284 We evaluated whether TDF causes tubulopathy when used as HIV preexposure prop

285 With TDF/FTC use, no clear association was found among PI use

286 analysis, the effectiveness was -49.0% with TDF (hazard ratio for infection, 1.49; 95% confidence in

287 nce interval [CI], 0.97 to 2.29), -4.4% with TDF-FTC (hazard ratio, 1.04; 95% CI, 0.73 to 1.49), and

288 tment-naive participants initiating ART with TDF/FTC, no differences in lean mass and regional fat we

289 P 2139-Mg or REP 2165-Mg in combination with TDF + pegIFN compared with TDF + pegIFN alone through th

290 s were safe and well tolerated compared with TDF + FTC; this study was not powered for efficacy.

291 combination with TDF + pegIFN compared with TDF + pegIFN alone through the first 48 weeks of therapy

292 FTC-EFV) (901 of 2472 [36.4%]) compared with TDF-FTC and nevirapine (NVP) (317 of 760 [41.7%]; ARR, 1

293 s were safe and well-tolerated compared with TDF-FTC in U.S. women.

294 Compared with TDF-FTC-EFV, all other regimens were associated with hig

295 and bone mineral density loss compared with TDF.

296 tion did not worsen on LDV/SOF regimens with TDF.

297 significantly lower than TFV C24 in SP with TDF, but 9.6-fold higher than the 50% inhibitory concent

298 T2D risk was inversely associated with TDFs [HR for quintile 5 compared with quintile 1: 0.59 (

299 -containing ART and 44 receiving ART without TDF (HSV-2 seroconversion incidence, 6.42 and 6.63 cases

300 R, 0.04-0.30]; n = 100), and LDV/SOF without TDF (0.15 [IQR, 0.00-0.30]; n = 423).